Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27779108 | 0.80 | BACE1 (0.53) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL28313335 | 0.79 | HDAC1 (0.45) | BACE1HDAC1HDAC2TLR2ERN1 | |
| SCHEMBL16974286 | 0.79 | HDAC1 (0.43) | BACE1HDAC1HDAC2TLR2ERN1 | |
| SCHEMBL2322461 | 0.78 | BACE1 (0.55) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL1599686 | 0.77 | BACE1 (0.58) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL14925243 | 0.77 | BACE1 (0.53) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL14780983 | 0.77 | BACE1 (0.53) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL30718905 | 0.77 | BACE1 (0.53) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL1599323 | 0.77 | BACE1 (0.53) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL5050008 | 0.77 | BACE1 (0.53) | BACE1HDAC1HDAC2TLR2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499127-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2499115-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-09-19 | — | — | EP | disclosed |
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2011091446-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011059887-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059850-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010127208-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-04 | — | — | WO | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| EP-2044018-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | Pfizer Japan, Inc. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008007211-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | BACE1 1255/4885HDAC1 2344/4885HDAC2 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.